Stay updated on Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.

Latest updates to the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedNote added to Study Record Dates showing the last known status as reported by National Cancer Centre, Singapore on 2023-10 and marked as Verified Unknown status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check17 days agoChange DetectedThe new screenshot shows minor UI refinements such as spacing, typography, and small layout adjustments across sections; there are no changes to core study details like eligibility criteria, endpoints, enrollment, or location. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check38 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference3%

- Check45 days agoChange DetectedUpdated page version to v3.1.0 and added a new contact phone number; removed the previous version tag v3.0.2.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the Back to Top element was removed; no core content, pricing, stock, or time-slot information was altered.SummaryDifference0.2%

- Check67 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

Stay in the know with updates to Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.